Cerebellar Network Compensation and Functional Connectivity Shifts in Parkinson’s Disease

Continued Evaluation of Safety, Tolerability, and Clinical Outcomes in Participants with Parkinson’s Disease Throughout Three Years After Bemdaneprocel Administration

CSM-101 is a Brain-penetrant Small Molecule Agonist of TRPML1 for Parkinson’s-related Disorders

The Small Molecule VQ-101 Demonstrates Sustained Lysosomal Glucocerebrosidase (GCase) Activation in Idiopathic Parkinson’s Disease